Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.01 | N/A | +13.95% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.01 | N/A | +13.95% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of optimism regarding their drug portfolio. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the strong performance in their key drug segments.
They expressed confidence in ongoing clinical trials and pipeline developments.
Bristol Myers Squibb's earnings report shows a solid EPS beat, which indicates strong underlying performance. However, the stock declined by 1.9%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more comprehensive information on the company's future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALLIBURTON CO
Jul 23, 2018